{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T03:22:36Z","timestamp":1775618556991,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T00:00:00Z","timestamp":1536019200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1038\/s41409-018-0298-y","type":"journal-article","created":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T12:01:03Z","timestamp":1536062463000},"page":"531-537","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Veno-occlusive disease after high-dose busulfan\u2013melphalan in neuroblastoma"],"prefix":"10.1038","volume":"55","author":[{"given":"Tal","family":"Schechter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelio","family":"Perez-Albuerne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0676-2626","authenticated-orcid":false,"given":"Tiffany F.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith S.","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Essa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami V.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haydar","family":"Frangoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Yanik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7699-1061","authenticated-orcid":false,"given":"L. Lee","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jacobsohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9862-510X","authenticated-orcid":false,"given":"Morris","family":"Kletzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Ranalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Soni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1799-2582","authenticated-orcid":false,"given":"Alix E.","family":"Seif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Grupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C.","family":"Dvorak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,4]]},"reference":[{"key":"298_CR1","unstructured":"Bleyer A, OLM Barr R, Ries LAG. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. NIH Pub. No. 06-5767. Bethesda, MD: National Cancer Institute; 2006."},{"key":"298_CR2","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1200\/JCO.2007.13.8925","volume":"27","author":"KK Matthay","year":"2009","unstructured":"Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children\u2019s Oncology Group study. J Clin Oncol. 2009;27:1007\u201313.","journal-title":"J Clin Oncol"},{"key":"298_CR3","first-page":"CD006301","volume":"8","author":"B Yalcin","year":"2013","unstructured":"Yalcin B, Kremer LC, Caron HN, van Dalen EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev. 2013;8:CD006301","journal-title":"Cochrane Database Syst Rev"},{"key":"298_CR4","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S1470-2045(13)70309-7","volume":"14","author":"SG Kreissman","year":"2013","unstructured":"Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013;14:999\u20131008.","journal-title":"Lancet Oncol"},{"key":"298_CR5","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(17)30070-0","volume":"18","author":"R Ladenstein","year":"2017","unstructured":"Ladenstein R, Potschger U, Pearson ADJ, Brock P, Luksch R, Castel V, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1\/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017;18:500\u201314.","journal-title":"Lancet Oncol"},{"key":"298_CR6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/pbc.24433","volume":"60","author":"JR Park","year":"2013","unstructured":"Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KK, et al. Children\u2019s Oncology Group\u2019s 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2013;60:985\u201393.","journal-title":"Pediatr Blood Cancer"},{"key":"298_CR7","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1200\/JCO.2010.34.3293","volume":"29","author":"JR Park","year":"2011","unstructured":"Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children\u2019s Oncology Group study. J Clin Oncol. 2011;29:4351\u20137.","journal-title":"J Clin Oncol"},{"key":"298_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/petr.12202","volume":"18","author":"S Soni","year":"2014","unstructured":"Soni S, Pai V, Gross TG, Ranalli M. Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children\u2019s Oncology Group (COG) induction platform for high-risk neuroblastoma: early results from a single institution. Pediatr Transplant. 2014;18:217\u201320.","journal-title":"Pediatr Transplant"},{"key":"298_CR9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/bmt.2012.276","volume":"48","author":"AE Seif","year":"2013","unstructured":"Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, et al. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children\u2019s Oncology Group study ANBL00P1. Bone Marrow Transplant. 2013;48:947\u201352.","journal-title":"Bone Marrow Transplant"},{"key":"298_CR10","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","volume":"11","author":"GM Brodeur","year":"1993","unstructured":"Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466\u201377.","journal-title":"J Clin Oncol"},{"key":"298_CR11","unstructured":"IV Busulfex (Busulfan) Package Insert. Tokyo, Japan: Otsuka America Pharmaceutical, Inc; 2009."},{"key":"298_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/hep.1840040121","volume":"4","author":"GB McDonald","year":"1984","unstructured":"McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4:116\u201322.","journal-title":"Hepatology"},{"key":"298_CR13","first-page":"197","volume":"10","author":"HM Shulman","year":"1992","unstructured":"Shulman HM, Hinterberger W. Hepatic veno-occlusive disease--liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant. 1992;10:197\u2013214.","journal-title":"Bone Marrow Transplant"},{"key":"298_CR14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","volume":"44","author":"RJ Jones","year":"1987","unstructured":"Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778\u201383.","journal-title":"Transplantation"},{"key":"298_CR15","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127:1656\u201365.","journal-title":"Blood"},{"key":"298_CR16","unstructured":"Williams B, Mandrekar JN, Mandrekar SJ, Cha SS, Furth AF. Finding optimal cutpoints for continuous covariates with binary and time-to-event outcomes. Report No.: 79. Rochester, Minnesota: Mayo Foundation; 2006."},{"key":"298_CR17","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2307\/2529881","volume":"38","author":"R Miller","year":"1982","unstructured":"Miller R, Siegmund D. Maximally selected chi square statistics. Biometrics. 1982;38:1011\u20136.","journal-title":"Biometrics"},{"key":"298_CR18","first-page":"1396","volume":"90","author":"S Cesaro","year":"2005","unstructured":"Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G, et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica. 2005;90:1396\u2013404.","journal-title":"Haematologica"},{"key":"298_CR19","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","volume":"379","author":"S Corbacioglu","year":"2012","unstructured":"Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012;379:1301\u20139.","journal-title":"Lancet"},{"key":"298_CR20","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.bbmt.2017.07.021","volume":"23","author":"RPS Bajwa","year":"2017","unstructured":"Bajwa RPS, Mahadeo KM, Taragin BH, Dvorak CC, McArthur J, Jeyapalan A, et al. Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolescents, Part 1: Focus on Investigations, Prophylaxis, and Specific Treatment. Biol Blood Marrow Transplant. 2017;23:1817\u201325.","journal-title":"Biol Blood Marrow Transplant"},{"key":"298_CR21","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3324\/haematol.2010.028027","volume":"95","author":"JJ Lahuerta","year":"2010","unstructured":"Lahuerta JJ, Mateos MV, Martinez-Lopez J, Grande C, de la Rubia J, Rosinol L, et al. Busulfan 12 mg\/kg plus melphalan 140 mg\/m2 versus melphalan 200 mg\/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA\/GEM2000 study. Haematologica. 2010;95:1913\u201320.","journal-title":"Haematologica"},{"key":"298_CR22","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/sj.bmt.1704275","volume":"32","author":"J Bouligand","year":"2003","unstructured":"Bouligand J, Boland I, Valteau-Couanet D, Deroussent A, Kalifa C, Hartmann O, et al. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplant. 2003;32:979\u201386.","journal-title":"Bone Marrow Transplant"},{"key":"298_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbmt.2012.08.009","volume":"19","author":"M Blanes","year":"2013","unstructured":"Blanes M, Lahuerta JJ, Gonzalez JD, Ribas P, Solano C, Alegre A, et al. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant. 2013;19:69\u201374.","journal-title":"Biol Blood Marrow Transplant"},{"key":"298_CR24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/pbc.24713","volume":"61","author":"D Valteau-Couanet","year":"2014","unstructured":"Valteau-Couanet D, Le Deley MC, Bergeron C, Ducassou S, Michon J, Rubie H, et al. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy. Pediatr Blood Cancer. 2014;61:977\u201381.","journal-title":"Pediatr Blood Cancer"},{"key":"298_CR25","first-page":"3678","volume":"56","author":"JP Gibbs","year":"1996","unstructured":"Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res. 1996;56:3678\u201381.","journal-title":"Cancer Res"},{"key":"298_CR26","doi-asserted-by":"publisher","first-page":"7952","DOI":"10.1074\/jbc.M009400200","volume":"276","author":"CM Paumi","year":"2001","unstructured":"Paumi CM, Ledford BG, Smitherman PK, Townsend AJ, Morrow CS. Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. J Biol Chem. 2001;276:7952\u20136.","journal-title":"J Biol Chem"},{"key":"298_CR27","first-page":"114","volume":"126","author":"HM Shulman","year":"1987","unstructured":"Shulman HM, Luk K, Deeg HJ, Shuman WB, Storb R. Induction of hepatic veno-occlusive disease in dogs. Am J Pathol. 1987;126:114\u201325.","journal-title":"Am J Pathol"},{"key":"298_CR28","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/bmt.2016.109","volume":"51","author":"ME Dourthe","year":"2016","unstructured":"Dourthe ME, Ternes N, Gajda D, Paci A, Dufour C, Benhamou E, et al. Busulfan-Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed-unexposed study evaluating the clinical impact of the order of drug administration. Bone Marrow Transplant. 2016;51:1265\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"298_CR29","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/pbc.25893","volume":"63","author":"AV Desai","year":"2016","unstructured":"Desai AV, Seif AE, Li Y, Getz K, Fisher BT, Huang V, et al. Resource utilization and toxicities after carboplatin\/etoposide\/melphalan and busulfan\/melphalan for autologous stem cell rescue in high-risk neuroblastoma using a National Administrative Database. Pediatr Blood Cancer. 2016;63:901\u20137.","journal-title":"Pediatr Blood Cancer"},{"key":"298_CR30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/petr.12638","volume":"20","author":"Y Elborai","year":"2016","unstructured":"Elborai Y, Hafez H, Moussa EA, Hammad M, Hussein H, Lehmann L, et al. Comparison of toxicity following different conditioning regimens (busulfan\/melphalan and carboplatin\/etoposide\/melphalan) for advanced stage neuroblastoma: experience of two transplant centers. Pediatr Transplant. 2016;20:284\u20139.","journal-title":"Pediatr Transplant"},{"key":"298_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255\u201367.","journal-title":"Ann Intern Med"},{"key":"298_CR32","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","volume":"85","author":"SI Bearman","year":"1995","unstructured":"Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;85:3005\u201320.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0298-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0298-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0298-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:12:51Z","timestamp":1684617171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0298-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,4]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["298"],"URL":"https:\/\/doi.org\/10.1038\/s41409-018-0298-y","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,4]]},"assertion":[{"value":"28 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CCD has served on advisory boards and consulted for Jazz Pharmaceuticals (manufacturer of defibrotide). The other authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}